A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PCOD / polycystic ovarian disease

[Related PubMed/MEDLINE]
Total Number of Papers: 202
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PCOD  (>> Co-occurring Abbreviation)
Long Form:   polycystic ovarian disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Which laboratory/ultrasonographic parameters affect the severity of hirsutism? FSH, LH
2020 Correlation of Cutaneous Manifestations with Body Mass Index, Blood Glucose, and Hormonal Levels in Patients with Polycystic Ovarian Disease. BMI, DHEAS, FSH, LH
2019 Impact of Bariatric Surgery on Female Reproductive Health and Maternal Outcomes. LAGB, LBW, LSG, NVD, RYGB, SGA
2018 A Cross-sectional Study on the Proportion of Anxiety and Depression and Determinants of Quality of Life in Polycystic Ovarian Disease. QOL
2018 Gynecological problems among adolescent girls in a tertiary care centre of South Andaman district. GOPD
2018 Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease. CCR-PCOD, IR, LOD, TNF-alpha
2017 Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent. INSL3, WHR
2017 Evaluation of tumor necrosis factor alpha serum level in obese and lean women with clomiphene citrate-resistant polycystic ovary disease. FAI, IR, obese CCR-PCOD, TNF-alpha
2016 Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy. GDM
10  2014 GC-MS analysis of Cocus nucifera flower extract and its effects on heterogeneous symptoms of polycystic ovarian disease in female Wistar rats. GSH, HDL, LDL, SOD, TC, TG
11  2013 Adrenal ganglioneuroma in a patient with polycystic ovarian disease (PCOD): a rare association. ---
12  2013 Effect of shatapushpa taila matra basti and pathadi kwatha on poly cystic ovarian disease. ---
13  2012 Bacterial vaginosis and infertility: cause or association? BV
14  2011 Mutation spectrum of fork-head transcriptional factor gene (FOXL2) in Indian Blepharophimosis Ptosis Epicanthus Inversus Syndrome (BPES) patients. BPES
15  2007 [Mechanism of action of insulin sensitizer agents in the treatment of polycystic ovarian syndrome]. PPARgamma, SHBG
16  2006 An evolutionary concept of polycystic ovarian disease: does evolution favour reproductive success over survival? ---
17  2006 Ovulation induction by antiestrogens in an Indian tropical vespertillionid bat, Scotophilus heathi. ENC
18  2006 Polycystic ovarian disease: the adrenal connection. CASH, PCO
19  2005 Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. ART, COH, GnRH, LH
20  2004 Commentary: Polycystic ovarian disease (PCOD): a misnomer, looking for a new name. PFOD
21  2004 Normal p21Ras/MAP kinase pathway expression and function in PBMC from patients with polycystic ovary disease. PBMC, PHA
22  2003 Regulation of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of MMP, and progesterone secretion in luteinized granulosa cells from normally ovulating women with polycystic ovary disease. EGF, MMP-9, PKA, PKC, PTK
23  2002 Cyclic estrogen-progestin hormone therapy as a new therapeutic approach in the treatment of functional alterations of the hypothalamus-pituitary-ovary axis: case reports. ---
24  2001 Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. IR, MTF
25  2001 Ovarian size and response to laparoscopic ovarian electro-cauterization in polycystic ovarian disease. ---
26  2001 Plasma beta-endorphin levels in obese and non-obese patients with polycystic ovary disease. BMI, LH, SHBG
27  2001 Polycystic ovary disease and the risk of pregnancy-induced hypertension. hMG
28  2001 The effect of androstenedione/estrone supplementation on cortical and cancellous bone in the young intact female monkey: a model for the effects of polycystic ovarian disease on the skeleton? B.Ar, BMD, DPA
29  2000 Diagnosis of polycystic ovary disease in obese women with a 24-hour hormone profile after buserelin stimulation. BSRL
30  2000 LH-RH analogues: I. Their impact on reproductive medicine. BPH, COS-ART, FSH, IVF-ET, LHRH
31  2000 Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease. ---
32  2000 Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. BHP, IVF-ET, LHRH
33  2000 The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment. FSH, GnRH, LH, OC
34  2000 The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease. FSH, GnRH, IVF, LH
35  2000 [Polycystic ovary syndrome as a multisystemic endocrinopathy]. ---
36  1999 Circulating levels of immunoreactive beta-endorphin in polycystic ovary syndrome. LH
37  1999 Hyperinsulinemia in polycystic ovary disease. ---
38  1999 Limited ovarian stimulation results in the recovery of mature oocytes in polycystic ovarian disease patients: a preliminary report. hMG, ICSI
39  1999 Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea. ---
40  1999 [Polycystic ovary syndrome--only relevant in reproductive medicine?]. ---
41  1998 Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease. AUC, OGTT
42  1998 Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. SHBG
43  1998 The role of three-dimensional ultrasonographic images in ovarian measurement. ---
44  1998 [The polycystic ovary syndrome associated with ovarian tumor]. ---
45  1997 Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms. CPA, DHEAS, EE, GnRHa, OC
46  1997 Polycystic ovary syndrome. An autoimmune disease? ---
47  1997 Pregnancy in infertile PCOD patients. Complications and outcome. ---
48  1996 Clinical and hormonal effects of gonadotropin-releasing hormone agonist plus an oral contraceptive in severely hirsute patients with polycystic ovary disease. CPA, LA, OC, SHBG
49  1996 Combined Laparoscopic Treatment of Polycystic Ovary Disease and Gallstones ---
50  1996 Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease. CC, OC, SHBG
51  1996 Low-dose follicle-stimulating hormone treatment for polycystic ovarian disease. FSH
52  1996 Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression. GnRHa, LH, OC
53  1996 Transvaginal color Doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary disease. ---
54  1996 Treatment of polycystic ovary disease with laparoscopic low-watt bipolar electrocoagulation of the ovaries. ---
55  1995 Effect of opioid blockade on insulin metabolism in polycystic ovarian disease. C-peptide, OGTT
56  1995 Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. OGTT
57  1995 GnRH analog administration in patients with polycystic ovarian disease. DHEAS, FSH, GnRH, LH
58  1995 Polycystic ovary disease. A risk factor for gestational diabetes? OGTT
59  1995 Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility. OHSS
60  1995 Serum insulin in clomiphene responders and nonresponders with polycystic ovarian disease. AUC, BMI, CC, DHEAS, free-T, OGTT
61  1995 Total renin after gonadotropin stimulation in polycystic ovarian disease. FF
62  1994 Androgen receptor expression in human ovarian and uterine tissue of long-term androgen-treated transsexual women. AR
63  1994 Changes in serum immunoreactive inhibin during ovulation induction in women with amenorrhea. hMG, IR, pFSH
64  1994 Characterization of 24-h cortisol release in obese and non-obese hyperandrogenic women. ---
65  1994 Effect of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease. DOPAC, DOPEG, free-T, SHBG
66  1994 Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. ---
67  1994 Laparoscopic treatment of polycystic ovarian disease. ---
68  1994 Lipoprotein lipids in androgen excess--a study among Indian women. ---
69  1994 Long-term follow-up in 206 infertility patients with polycystic ovarian syndrome after laparoscopic electrocautery of the ovarian surface. LEOS
70  1994 Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease. GH, IGFBP-1, LH, SHBG
71  1994 Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. ---
72  1994 Serum immunoreactive inhibin levels in polycystic ovarian disease (PCOD) and hypogonadotropic amenorrhea. IR
73  1994 Serum testosterone, androstenedione and luteinizing hormone levels after short-term medroxyprogesterone acetate treatment in women with polycystic ovarian disease. LH, MPA
74  1994 Sex hormones regulate ABR latency. ABR, POF
75  1994 Treatment of hirsutism with flutamide and a low-dosage oral contraceptive in polycystic ovarian disease patients. DHT, OC
76  1994 [Insulin resistance in the pathogenesis of polycystic ovarian disease (PCOD)]. ---
77  1993 A comparative study of three ovulation induction protocols in polycystic ovarian disease patients in an in vitro fertilization/embryo transfer program. CC, GnRHa, hCG, hMG, IVF-ET, LH
78  1993 Adhesion formation after laparoscopic electrocoagulation of the ovarian surface in polycystic ovary patients. ---
79  1993 Clinical and endocrine effects of laser vaporization in patients with polycystic ovarian disease. DHEA, FSH, LH
80  1993 Endocrine changes and clinical outcome after laparoscopic ovarian resection in women with polycystic ovaries. FSH, GnRH, LH
81  1993 Immunohistochemical localization of renin and angiotensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. GCs, PCO
82  1993 Insulin hypersecretion together with high luteinizing hormone concentration augments androgen secretion in oral glucose tolerance test in women with polycystic ovarian disease. LH
83  1993 Insulin resistance improves in hyperandrogenic women treated with Lupron. SI
84  1993 Ovarian electrocauterization causes LH-regulated but not insulin-regulated endocrine changes. LH, SHBG
85  1993 Ovarian electrocautery: responders versus non-responders. FSH, LH
86  1993 Pharmaco-dynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. FSH, hMG, LH
87  1993 Polycystic ovarian disease (PCOD)--pregnancy rate and outcome in in vitro fertilization. ---
88  1993 Polycystic ovaries in non-obese and obese patients: possible pathophysiological mechanism based on new interpretation of facts and findings. GH, IGF-I, IGFBP-I, LH, SHBG
89  1993 Serum levels of insulin-like growth factor binding protein-1 and ovulatory responses to clomiphene citrate in women with polycystic ovarian disease. CC, IGF-I, IGFBP-1, OGTT
90  1993 The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. GnRH, LH
91  1993 Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog. EE
92  1992 Comparison of luteinizing hormone pulsatility in the serum of women suffering from polycystic ovarian disease using a bioassay and five different immunoassays. IR-LH, mAb
93  1992 Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion. DEX, DHEAS, OGTT
94  1992 Endoscopic carbon dioxide laser ovarian wedge resection in resistant polycystic ovarian disease. ---
95  1992 Implications of ultrasonically diagnosed polycystic ovaries. I. Correlations with basal hormonal profiles. PCO
96  1992 Implications of ultrasonically diagnosed polycystic ovaries. II. Studies of dynamic and pulsatile hormonal patterns. DHEAS, PCO
97  1992 Indications for in vitro fertilisation: changing trends: the Norfolk experience. DES, IVF
98  1992 Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction. DEX, DHEA, DHEAS, FSH, GnRHa, LH
99  1992 Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study. FSH, GnRHa, hMG
100  1992 Pulsatile luteinizing hormone secretion in hypothalamic amenorrhea, anorexia nervosa, and polycystic ovarian disease during naltrexone treatment. FSH, LH